Welcome to our dedicated page for Emmaus Life Scie SEC filings (Ticker: EMMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Emmaus Life Sciences, Inc. (EMMA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Emmaus is a commercial-stage biopharmaceutical company focused on Endari®, its prescription-grade L-glutamine oral powder for sickle cell disease, and its filings give detailed insight into financial performance, capital structure, and key agreements.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which Emmaus references in its press releases when discussing risks and uncertainties, including doubt about its ability to continue as a going concern. These reports typically include information on net revenues from Endari sales, operating expenses, income or loss from operations, other income or expense, liquidity, and stockholders’ deficit.
Emmaus also files multiple Form 8-K current reports to disclose material events. Recent 8-Ks describe an Exchange Agreement involving the issuance of common stock and a convertible promissory note in exchange for an outstanding convertible note, the resignation of a director, and the entry into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Under that license, Emmaus granted NeoImmuneTech exclusive rights to market, sell, and distribute Endari and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada, subject to specified conditions. The 8-Ks summarize terms such as upfront payments, royalties, conversion prices, and adjustment mechanisms for notes.
On Stock Titan, AI-powered tools can help interpret these EMMA filings by highlighting the sections that explain new licensing arrangements, changes in debt obligations, and references to going concern risks. Users can quickly locate information on Emmaus’ material definitive agreements, unregistered sales of securities, and other corporate actions without reading every page of the underlying documents. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, and 10-Ks for Emmaus Life Sciences are reflected promptly, while Form 4 and other ownership-related filings can be used to track insider and major holder activity where available.
Emmaus Life Sciences has entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT), building on a prior license that grants NIT exclusive rights to market and distribute Endari for sickle cell disease in the U.S., its territories and possessions, and Canada.
The new agreement provides that, once the License Agreement’s “Effective Date” occurs, Emmaus will supply Endari and any generic equivalents exclusively to NIT, and NIT will, with limited exceptions, purchase all of its product requirements from Emmaus at a price equal to Emmaus’ production cost plus a specified double‑digit percentage margin.
The Effective Date depends on NIT obtaining required regulatory approvals and other conditions, and may never be reached. Either party may terminate the License Agreement if the Effective Date has not occurred by October 1, 2026, unless the delay results from wrongful acts by Emmaus.
Emmaus Life Sciences entered into a License and Exclusive Distribution Agreement with NeoImmuneTech (NIT) giving NIT exclusive rights to market, sell, and distribute Endari and its generic equivalents for sickle cell disease in the U.S., its territories, and Canada. In return, Emmaus receives an upfront payment and ongoing royalties on NIT’s product sales.
Once the agreement’s “Effective Date” occurs, Emmaus will also become NIT’s exclusive supplier of Endari for this use and region at a price based on Emmaus’ production cost plus an agreed margin. The Effective Date depends on NIT obtaining required regulatory approvals and other conditions, and the agreement can be terminated if these are not met by October 1, 2026. If NIT does not achieve specified minimum annual sales after the Effective Date, its rights become nonexclusive, while Emmaus keeps all Endari rights outside this disease area and territory.
Emmaus Life Sciences, Inc. entered into an exchange agreement with a single noteholder on December 17, 2025. The company agreed to issue 6,332,692 shares of common stock valued at approximately $0.38 per share and a new convertible promissory note with a principal amount of
The cancelled note carried 10% annual interest and was convertible at $0.13 per share. The new note also bears 10% annual interest and is initially convertible at $0.01 per share, subject to quarterly reset to the average VWAP if that is lower, and to adjustment for stock splits and similar events. The principal on the new note is due on demand, and no additional cash consideration was exchanged. The securities will be issued without registration in reliance on the Section 3(a)(9) exemption.
Emmaus Life Sciences, Inc. reported a board change, disclosing that director Ian Zwicker resigned from the company’s board of directors on December 15, 2025, with the resignation to take effect on December 31, 2025. The filing does not describe any related financial effects or changes to the company’s operations, focusing solely on this governance update. Emmaus remains a Delaware corporation headquartered in Torrance, California, and the report was signed by Chairman and Chief Executive Officer Willis Lee.
Emmaus Life Sciences, Inc. filed a current report to note that it issued a press release on November 14, 2025 announcing its results of operations and financial condition for the three months ended September 30, 2025. The company attached this press release as Exhibit 99.1 and incorporated it by reference. The company also clarified that the earnings information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities filings.
Emmaus Life Sciences filed its Q3 2025 10-Q, highlighting a sharp revenue decline and liquidity strain alongside a going concern warning. Q3 revenue was $3.38 million versus $5.48 million a year ago, and the company posted a net loss of $2.08 million versus net income of $1.83 million in Q3 2024. Operating profit of $0.70 million was outweighed by other expense of $2.19 million, driven mainly by interest expense of $1.93 million.
For the nine months, revenue was $8.60 million versus $13.36 million. Cash was $0.29 million with current liabilities of $64.17 million, and total liabilities of $80.24 million against assets of $20.76 million, resulting in a stockholders’ deficit of $59.49 million. Management states there is substantial doubt about continuing as a going concern without restructuring debt and raising additional financing. The company also recorded a $0.53 million realized loss year‑to‑date on its Telcon convertible bond.